Sign in
CERE Stock Price, Chart, Stats & News
Cerevel Therapeutics Holdings, Inc.
Save
8.19B
Market cap
–
Current P/E
–
Forward P/E
CERE chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | -0.12% |
ROA | -34.81% |
ROE | -72.44% |
D/E | 0.71x |
Interest coverage ratio | -42.33x |
CERE valuation
P/E | – |
P/S | – |
P/B | 10.81x |
P/CF | -21.29x |
P/FCF | -23.67x |
P/OCF | -21.29x |
PEG | -0.17x |
EV multiple | -20.91x |
About
Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing treatments for a range of neuroscience disorders. The company boasts a robust pipeline of therapeutic candidates currently undergoing various phases of clinical evaluation. Key assets include emraclidine, a positive allosteric modulator (PAM) in Phase 1b trials for schizophrenia.
Similar securities
Based on sector and market capitalization
Report issue